What is it used for?
CALQUENCE in combination with bendamustine and rituximab is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). CALQUENCE is indicated for the treatment of adult patients with MCL who have received at least one prior therapy. CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).CALQUENCE in combination with bendamustine and rituximab is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). CALQUENCE is indicated for the treatment of adult patients with MCL who have received at least one prior therapy. CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- acalabrutinibacalabrutinib
- Form and strength
- CAPSULE, GELATIN COATED · 100 mgCAPSULE, GELATIN COATED · 100 mg
- Manufacturer / applicant
- ASTRAZENECA PHARMACEUTICALS LPASTRAZENECA PHARMACEUTICALS LP
Capsules:100 mg acalabrutinib size 1 hard gelatine capsules, with a yellow body and blue cap, marked in black ink with ‘ACA 100 mg’.Capsules:100 mg acalabrutinib size 1 hard gelatine capsules, with a yellow body and blue cap, marked in black ink with ‘ACA 100 mg’.
Safety and clinical review
- Serious and Opportunistic InfectionsSerious and Opportunistic Infections
- HemorrhageHemorrhage
- CytopeniasCytopenias
- Second Primary MalignanciesSecond Primary Malignancies
- Cardiac ArrhythmiasCardiac Arrhythmias
- Hepatotoxicity, Including Drug-Induced Liver InjuryHepatotoxicity, Including Drug-Induced Liver Injury
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is CALQUENCE used for?
CALQUENCE in combination with bendamustine and rituximab is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). CALQUENCE is indicated for the treatment of adult patients with MCL who have received at least one prior therapy. CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).CALQUENCE in combination with bendamustine and rituximab is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). CALQUENCE is indicated for the treatment of adult patients with MCL who have received at least one prior therapy. CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of CALQUENCE should I ask about?
CAPSULE, GELATIN COATED · 100 mgCAPSULE, GELATIN COATED · 100 mg
Read the primary sourceWhat determines the price of CALQUENCE?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using CALQUENCE?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.